Introduction {#Sec1}
============

Interactions of glycans, namely complex oligosaccharides attached to a protein or lipid mediate many important biological processes, such as pathogen recognition \[[@CR1]\], malignant transformation \[[@CR2]\], autoimmune disease \[[@CR3]\], neurological disorders \[[@CR4]\] and host-versus-graft rejection \[[@CR5]\]. Naturally occurring and adaptive anti-glycan antibodies are currently the object of both basic research \[[@CR6], [@CR7]\] and biomarker discoveries \[[@CR8]--[@CR12]\].

Ovarian cancer is the sixth most common cause of cancer-related death of women and the leading cause of death from gynaecological malignancies \[[@CR13]\]. Despite considerable efforts to improve early detection and advances in chemotherapy, intra-abdominal metastasis remains a major challenge in the clinical management of undifferentiated high FIGO (International Federation of Gynecology and Obstetrics) stage serous ovarian cancers with an overall five-year survival of 20%. This poor overall prognosis is due to multiple factors including a lack of early symptoms and specific screening methods, ineffective therapy for advanced or recurrent disease, and from limited understanding of the early-initiating events and stages of ovarian cancer development. Therefore, there is an urgent clinical need for a reliable, non-invasive and affordable serum-based screening test for ovarian cancers.

In a previous study we used the first custom-made high throughput printed glycan array (PGA, Cellexicon, San Diego, USA) and identified specific anti-glycan antibody patterns in blood of ovarian cancer patients compared to healthy controls \[[@CR11]\]. Whilst it is known that aberrant glycosylations are found in most cancers, only a limited number of human antibodies towards tumor associated carbohydrate antigens (TACA) have been evaluated for their potential significance in cancer biology. The printed glycan array \[[@CR6], [@CR14]\] consists of a library of over 200 glycans, including well known TACA. Linear modelling revealed 24 carbohydrate structures for which the amount of anti-glycan antibodies was significantly lower in the above mentioned non-mucinous ovarian borderline and cancer cohort as compared to the healthy patient cohort. The glycan structure with the most significant discriminatory ability was P~1~ (*Galα1-4Galβ1-4GlcNAcβ*; *P \<* 0.001), a member of the P blood group system.

In recent years a number of glycan based microarray platforms, based on specific (covalent or non-covalent) immobilization of chemically conjugated glycans on a modified surface, have been developed for high-throughput investigations of the glycome \[[@CR15]\]. Glycan-based arrays vary in ligand presentation, glycan origin (isolated from natural sources or chemically synthesized), assay conditions, detection method, microspheres (suspension array) and immobilization on flat surfaces (printed glycan array, ELISA); all of which contribute to the affinity and selectivity of binding \[[@CR16], [@CR17]\]. There is a crucial need for standardization and comparison between various forms of glycan microarrays, especially taking into account their proven scientific potential for translational research and subsequent clinical applications. The increasing number of high-throughput glycan array studies requires the application of different bioinformatical analyses for validation and comparison of datasets. However, to date, only a few reports comparing glycan microarrays and conventional ELISA have been performed. Most of these studies only investigated them in terms of sample size, dynamic range and sensitivity of measurement (detection limits) \[[@CR2], [@CR18]--[@CR20]\].

In this present study, which is in line with our previous development of a glycan-based suspension array, we compared three glycan-immunoassays for the detection of the most complicated glycan-binding protein class; antibodies in human plasma. These assays include (1) printed glycan array; (2) multiplex flow cytometric suspension assay; and (3) regular direct ELISA, the most established method. Printed Glycan Array (PGA) as one of the newest high-throughput microarray technologies \[[@CR6], [@CR14]\] allows the automated detection of an unlimited number of natural and synthesized glycans in one experimental setting. It is characterized by high sensitivity and a significant reduction of reagent consumption. The second approach, multiplex flow cytometric suspension assay (SA), incorporating fluorescent microspheres with distinct spectral addresses as a solid support for ligands, was recently developed for profiling of anti-glycan antibodies \[[@CR9], [@CR21]\]. The advantage of this assay is reflected by the flexibility and simultaneous detection of multiple ligands in one sample with minimal reagent consumption. The third method, conventional direct ELISA \[[@CR7], [@CR19], [@CR22], [@CR23]\], which allows assessment of a limited number of glycan-protein interactions, is well established and currently the most widely used method for this type of application. In both the PGA and ELISA glycans are positioned onto a flat surface; in PGA glycans are covalently attached to the surface of a glass slide in a monovalent form as ω-alkyl glycosides (Glyc-sp-NH~2~), whereas in ELISA they are physically adsorbed to polystyrene in multivalent form, as conjugates with a polyacrylamide or albumin carrier. In the case of suspension array (SA), glycans are coupled as end-biotinylated glycopolymers \[[@CR24]\] *via* streptavidin-biotin reaction to pre-modified fluorescent beads. All three glycan immunoassays display various detection specificities resulting in specific advantages and limitations. ELISA is most relevant for the investigation of a limited panel of glycans, and would be suitable for a preliminary survey of new glycan-binding partners. Printed glycan array allows broad glycan library screening, and suspension assay has advantages for the rapid and flexible multiplex detection of up to several dozen samples. Therefore, all three glycan assays could be used to study different aspects of glycan-antibody interactions.

We performed a comparative analysis using three glycan-based immunoassays for a cohort of 48 patients with and without ovarian cancer. Two target anti-glycan antibodies were selected, anti-blood group A/B trisaccharides \[[@CR6], [@CR25]--[@CR27]\] and our previously identified candidate P~1~ in order to investigate the expected anti-glycan antibody distribution in plasma for each assay.

Material and methods {#Sec2}
====================

Clinical cohort {#Sec3}
---------------

Blood samples were collected prospectively from 48 patients at the Department of Gynaecology, University Hospital Zurich, after written informed consent was given (Table [1](#Tab1){ref-type="table"}). Ethical approval for this study was granted by the appropriate Ethical Board in 2006 (to V.H.S., SPUK Canton of Zurich, Switzerland). Two venous blood samples (12 mL) were collected pre-operatively per patient in EDTA blood tubes (BD Vacutainer^®^, 0.184M EDTA, BD Diagnostics, Franklin Lakes, US) and stored on ice until further processing. Blood samples were centrifuged at 3000 *g* at 4°C for 10 min, and aliquots of the supernatant plasma frozen at −80°C. All collected blood samples were processed using the same protocol and within 3 h of their collection.Table 1Clinicopathological characteristics. Patient numbers and percentage (in brackets)Patient cohort (*n* = 48)Controls24 (50.0)Healthy controls15 (31.3)Benign tumours9 (18.7)Cancers24 (50.0)Serous cancerOvarian16(31.3)Peritoneal5 (10.4)Tubal3 (6.3)FIGO StageStage I / II3 (6.3)Stage III / IV20 (41.7)

**ELISA** NUNC MaxiSorp 96-well immunoplates (Thermo Fisher Scientific, Roskilde, Denmark) were coated with Glyc-PAA (Lectinity Holdings, Moscow, Russia), 10 μg/mL, 100 μl per well in carbonate buffer (50 mM Na~2~CO~3~/ NaHCO~3~, pH 9.6) for 12 h at 4°C. Carbohydrate-free PAA was applied as negative control. Plates were blocked with 1% *(w/v)* BSA (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) in PBS for 40 min at 37°C and washed four times with PBS containing 0.5% *(v/v)* Tween-20 after incubation. Plasma samples were diluted 1:1000 in incubation buffer (PBS, 0.3% *(w/v)* BSA, 0.02% *(v/v)* Tween 20), added to plates in duplicate and incubated for 60 min at 37°. Between each of the following steps plates were washed four times with PBS containing 0.5% *(v/v)* Tween-20: incubation with 100 μl per well of goat anti-human Ig (IgA + IgG + IgM) conjugated to long chain biotin for 60 min at 37° (Pierce, Rockford, IL, USA, 0.16 μg/mL in incubation buffer); streptavidin horse raddish peroxidase conjugate for 60 min at 37°C (Southern Biotechnology Associates, Inc., Birmingham, AL, USA, 0.083 μg/mL in incubation buffer); and chromogen substrate 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) for 5 min at RT. The peroxidase reaction was stopped by addition of equal volumes of 1M H~2~SO~4~. Absorbance was measured at 450 nm using a TECAN plate reader (Tecan Spectrafluor Plus, Tecan Trading AG, Männedorf, Switzerland).

**Suspension array (SA)** The Bio-Plex Suspension Array (Bio-Rad Laboratories, Hercules, CA, USA) is a multiplex analysis system that permits the simultaneous analysis of up to 100 different biomolecules in a single microplate well. The constituents of each well are drawn up into the flow-based Bio-Plex array reader, which quantifies each specific reaction based on its bead color using fluorescently labeled reporter molecules specific for each target protein followed by Bio-Plex Manager software data analysis. A 96-well Multiscreen HTS filter plate (Millipore Corp., Billerica, MA, USA) was soaked in 100 μl of antibody diluent for 5 min (PBS-0.05 M Tris, pH 7.2, 0.25% BSA, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Antibody diluent incorporating 2000 beads/well (50 μl/well) was added. The plate was washed three times with 100 μl of washing buffer (PBS-0.05 M Tris, pH 7.2) using a vacuum manifold (Bio-Rad, Munich, Germany). Human samples were added in duplicates to wells (in antibody diluent 1:40 (50 μl/well)) and agitated at 1,100 rpm for 30 s on a microplate shaker before incubation on a shaker (200--300 rpm) for 1 h at RT in the dark. After incubation, the plate was washed three times using washing buffer. Secondary antibodies (R-phycoerythrin conjugated goat anti-human Ig (IgM + IgG + IgA, H + L; Southern Biotechnology Associates Inc., Birmingham, AL, USA, 25 ng/well) were added and incubated for 30 min on the plate shaker in the dark. The plate was washed three times with washing buffer, beads were then resuspended and shaken for 30 s at 1,100 rpm in 100 μl of washing buffer before being analyzed on the Bio-Plex array reader. Data were acquired in real time analyzing 100 beads by their median fluorescence intensitiy (MFI) using a computer software package (Bio-Plex Manager 4.1; Bio-Rad Laboratories, Hercules, CA, USA).

**Coupling procedure** The end-biotinylated glycopolymers for coupling to fluorescent microspheres, Glyc-PAA-biot~1~, were produced in-house (Laboratory of Carbohydrates, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation). Biotinylated glycopolymers were coupled to fluorescent carboxylated beads of 5.5 μm diameter with distinct spectral "addresses" (Bio-Rad Laboratories Inc., Hercules, CA, USA). Each set of beads was embedded with a precise ratio of red and infrared fluorescent dyes allowing its identification by measuring the intensities of the two classifier fluorochromes. The stock vial of microspheres (1.25 × 10^7^ microspheres/mL) was vortexed for 30 s and sonicated for 30 s in a water bath prior its use. Bead suspension (100 μl; 1.25 × 10^6^ microspheres, 0.2 nmol --COOH groups in total, according to the supplier's information) was centrifuged for 4 min, 14,000 g at RT. The pellet was resuspended in bead wash buffer (100 μl; Bio-Plex amine coupling kit, Bio-Rad Laboratories Inc., Hercules, CA, USA) by vortexing and sonication, and washed by centrifugation as described above. After gentle removal of supernatant, the pellet was resuspended in 80 μl of bead activation buffer (Bio-Plex amine coupling kit, Bio-Rad Laboratories Inc., Hercules, CA, USA), vortexed and sonicated. Sulfo-*N*-hydroxysuccinimide sodium salt (S-NHS) and 1-ethyl-3-\[3,3-dimethylaminopropyl\]carbodiimide hydrochloride (EDC; Pierce Biotechnology, Rockford, IL, USA, both 50 mg/mL in activation buffer) were prepared immediately prior to use, and 10 μl of each solution was added to the bead suspension, followed by vortexing for 30 s. Beads were incubated on a vertical rotor in the dark for 20 min at RT. The activated beads were centrifuged and supernatant removed. The pellet was resuspended in 150 μl biotin-solution (0.1 M NaHCO~3~, pH 8.3, containing 1 μg (≈ 2 nmol) of biotin-NH(CH~2~)~6~NH~2~. Lectinity Holdings, Moscow, Russia) and incubated on a vertical rotor with medium speed for 2 h at RT in the dark. Obtained biotinylated beads were pelleted by centrifugation and resuspended in 150 μl of 50 mM ethanolamine (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) in 0.1 M NaHCO~3~, pH 9.0 to quench unbound activated groups. Beads, protected from light, were agitated on a rotator for 30 min at RT and centrifuged. The pellet was washed twice with 500 μl PBS, pH 7.4 and resuspended in streptavidin-solution (400 pmol streptavidin in 150 μl PBS; Bio-Rad Laboratories Inc., Hercules, CA, USA). Suspended bead were vortexed and agitated on a rotator in the dark for 2 h at RT or 12 h at 4°C. Beads were washed twice with 500 μl PBS followed by centrifugation. Glyc-PAA-biot~1~ solutions in water (20 pmol end-biotin labeled Glyc-PAA, ∼30 kDa, Glyc contents - 20% mol) \[[@CR24]\], were added with 1.25 × 10^6^ streptavidin-coated beads in 150 μl PBS to the reaction tubes. The mixture was protected from light and agitated on a rotator for 6 h at RT. Modified microspheres were centrifuged, supernatant removed and beads washed twice with 500 μl of bead storage buffer (Bio-Rad Laboratories Inc., Hercules, CA, USA). Beads were centrifuged and resuspended in 100 μl of bead storage buffer and concentration determined using a hemocytometer (Roth AG, Karlsruhe, Germany) before storing at 4°C, protected from light.

**Printed glycan array (PGA)** Printed glycan array slide fabrication and high-throughput profiling was performed as previously described \[[@CR6], [@CR11], [@CR14]\]. Briefly, monomeric glycans as ω-aminopropyl glycosides of 95--98% purity (Lectinity Holdings, Moscow, Russia) were diluted in 300 mM phosphate buffer pH 8.5, containing 0.005% Tween 20 and printed by robotic pin deposition on *N-*hydroxysuccinimide activated glass slides (Nexterion Slide H, Schott, Jena, Germany). Glycans were printed at a 50 μM concentration in eight replicates. Free *N-*hydroxysuccinimide activated groups were blocked with 50 mM ethanolamine in 50 mM borate buffer at a final pH of 9.2. Slides were then rinsed with deionized water, dried and stored at room temperature in a desiccator. Each plasma sample was diluted 1:15 with PBS containing 0.1% *v/v* Tween20 and 3% *w/v* BSA, thoroughly vortexed for 15 s and incubated at 37°C for 15 min to dissolve potential lipid aggregates. Samples were transferred to the array slides and gently rocked in a sealed humidified incubator for 2 h at 37°C. Unbound sample components were washed with a series of 0.1% and 0.001% Tween-20 in PBS. Antibody solution and goat anti-human IgA + IgG + IgM conjugated to long chain biotin (Pierce Biotechnology, Rockford, IL, USA, 1:100 (20 μg/mL) in PBS containing 0.1% Tween-20 and 3% BSA) was added. Slides were incubated at RT in a humidified chamber for 45 min and then washed. Bound antibodies were visualized by incubating slides with fluorescent dye streptavidin solution (Alexa Fluor^555^, Molecular Probes, Invitrogen, Carlsbad, CA, USA, 1:1000 in PBS/0.1% Tween-20) at RT for 30 min. Fluorescence signals corresponding to glycan-bound antibodies were measured and quantified using ImaGene analysis software version 6.1 and 7.5 (BioDiscovery, El Segundo, USA). Signals were measured as total signal intensity (medTSI) per glycan and were expressed as median across eight intra-array replicates. In a prior discovery approach we screened plasma of non-mucinous ovarian cancer patients in comparison to healthy controls and revealed anti-P~1~ antibodies to be the most specific differentiating anti-glycan antibody. Apart from the standard ABO blood group system we have therefore used anti-P~1~ in this comparative analysis as an example of a new biomarker identified by PGA only.

Controls and validation procedures {#Sec4}
----------------------------------

Due to the known high expression levels in healthy controls α-rhamnose was used as a "positive biological control" in the PGA experiments \[[@CR10]\]. Aminoglucitol, an opened reduced form of *D*-glucose which is not present as a structural component of regular glycosylation, has shown to be negative for anti-glycan binding at similar values to the technical background \[[@CR6], [@CR11]\]. We therefore used it as a negative biological control in both PGA and SA experiments, where MFI signals for aminoglucitol binding did not exceed 200 and were close to the technical cut-off in all individual samples (data not shown). A glycan-free polymer (PAA) was used in ELISA as a control for non-specific binding and displayed lower signals than the lowest signals for Glyc-PAA coating in all cases (data not shown). Human polyclonal antibodies against A/B blood group antigens were used to test the coupling effectiveness in SA. Anti-glycan antibodies were purified from pooled human plasma of the same blood group using affinity chromatography as previously described \[[@CR7], [@CR21]\]. Polyclonal anti-glycan antibodies bound to cognate glycans in a dose-dependent manner displayed no or very low cross-reactivity to other glycans in both SA and ELISA (data not shown).

Anti-A/B antibody screening {#Sec5}
---------------------------

The well known ABO blood group carbohydrate antigens were used as a model for the comparison of our three glycan immunoassays. ABO-specific antibodies (isohaemagglutinins) belong to a group of naturally occurring antibodies \[[@CR28]\] which can be detected by the haemagglutination test, ELISA \[[@CR22], [@CR23]\] and flow cytometry \[[@CR29]\]. Blood group information was available for 31 patients, of whom 13 patients had blood group A (41.9%), 6 patients blood group B (19.3%), 2 patients blood group AB (6.4%) and 10 patients blood group O (32.2%). Antibody profiles for A~tri~ (*GalNAcα1-3* (*Fucα1-2)Galβ*) and B~tri~ (*Galα1-3(Fucα1-2)Galβ*) blood group antigens were generated using SA, ELISA and PGA. Raw data were acquired for all technologies in different units; values varied from 74 to 13595 (MFI, SA), from 0.152 to 2.305 (OD, 450 nm, ELISA) and from 0 to 51.28\*10^5^ (medTSI, PGA). Anti-A/B antibody levels were calculated as distribution of the median and additional median absolute deviation.

Statistical analysis {#Sec6}
--------------------

In the combination of three different immuno-assays one of the major problems is the absence of a 'gold' standard method, which means there is no experimental approach available, which can be taken as a norm of measuring anti-glycan antibodies. Neither has an internal standard nor a background threshold been established , and the data values achieved in each method are independent from each other, which make the direct comparison impossible: (A) ELISA values reflect the oxidized product of the chromogen TMB (3, 3′, 5, 5′-tetramethylbenzidine) and is a substrate conversion based on an enzymatic reaction; (B) printed glycan array (PGA) and suspension array (SA) (R-phycoerythrin) results are achieved due to fluorescence measurements. These differences lead to data values, which require data mining before method comparison. When dealing with parameters of different units and scales it is very important to standardize or normalize data in order to allow for a reliable comparison. Here we used standardization of data as it transforms datasets into a mean zero and a unit variance and keeps ranges similar and variables different. This is also the most commonly used method for normalization and comparison of methods incorporating differing datasets. Whilst PGA data were pre-processed \[[@CR6]\], SA raw data were log-transformed to improve interpretability and visualization. To solve the problem of different data values, all data sets were standardized as follows: z = (x~i~ -- x~mean~)/x~sd.~ Standardized data (z) were generated for each vector data set (x~i~) by subtraction by their mean (x~mean~) and division of their standard deviation (x~sd~), and called 'standardized antibody measurements' (SAM). Combined graphical and statistical interpretations of method-comparison studies were performed and included scatter plots combined with correlation and regression analysis \[[@CR30]\]. Data analysis, including calculation of mean, median, standard deviation and coefficient of variation was performed using the open source statistical programming language R (<http://CRAN.R-project.org/>, version 2.8.1). Statistically significant differences were proved for each method by the Wilcoxon rank sum test or student *t* test. Concordance correlation coefficients (r~CCC~) \[[@CR31]\], which evaluate the degree to which pairs of observations fall on the 45° line through the origin, were calculated and compared within all independent methods (R package epiR). Direct comparison of two methods was performed using parametric linear regression \[[@CR32], [@CR33]\]. Non-parametric testing of median signals among all known blood groups was measured using the Kruskal-Wallis rank sum test. For comparisons of high *versus* low anti-glycan antibody levels in correlation with known blood groups, sensitivity, specificity and area under the curve (AUC) were calculated for each method (R package ROCR \[[@CR34]\]). The best cut-off between observed false negative and false positive values was described as the "precision-recall break-even point" \[[@CR34]\], the point at which precision equals recall and predictions are made due to the prevalence within the data given. All *p*-values \< 0.05 were taken as significant.

Results {#Sec7}
=======

Detection of anti-A and anti-B antibodies {#Sec8}
-----------------------------------------

Using PGA, we observed higher antibody binding levels for B~tri~ than for A~tri~ with higher individual variability of the latter, consistent with the literature \[[@CR6]\]. The same pattern was observed in ELISA, followed by lower individual variability of both anti-glycan antibodies, indicated by median absolute deviation (data not shown). In contrast to PGA and ELISA, data using SA revealed no significant difference between general levels of anti-A and anti-B antibody binding, accompanied by higher individual variability in anti-A antibody binding.

Direct comparison of all three methods, based on scatter plots and linear regression model revealed a pattern of positive correlation, ranging from moderate to high (Fig. [1](#Fig1){ref-type="fig"}). The observations were found to be subject (here: glycan) independent, which was indicated by absence of difference in both linear regression models in all three binary comparisons. The highest Concordance Correlation Coefficients (r~ccc~) was observed between PGA and SA (Fig. [1](#Fig1){ref-type="fig"}, with r~ccc~ 0.83 for A~tri~ and 0.70 for B~tri~). These positive correlations were displayed by the proximity of linear regression lines to the equality line for both antigens. Moderate correlation was observed for ELISA and SA in A~tri~ and B~tri~ antigens (r~ccc~ 0.68 and 0.71, respectively, Fig. [1](#Fig1){ref-type="fig"}), with the weakest correlation between ELISA and PGA (r~ccc~ of 0.54 (A~tri~) and 0.41 (B~tri~)). Anti-glycan antibody levels correlated significantly with each other across all three methods (*p* \< 0.05). In PGA *vs.* SA and ELISA *vs.* PGA the correlation characteristics were slightly more pronounced for A antigen than for B antigen, which is indicated by higher r~ccc~ values (r~ccc~ of 0.83 *vs.* 0.7 in PGA *vs.* SA and 0.54 *vs.* 0.41 in ELISA *vs.* PGA, Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Comparison of glycan-based immunoassays using ABO blood groups. Scatter plots demonstrating the correlation between printed glycan array, suspension array and ELISA. The *x*- and *y*- axes represent standardized signals for each method, the dashed line indicates linear regression for A~tri~ (empty dots) and dotted line for B~tri~ (filled dots). The solid line indicates intercept of 0 and slope of 1. Each dot is represented by two-method measurement of one plasma sample (*n* = 31). R~ccc~ represents concordance correlation coefficient per blood group including the 95% confidence interval in brackets

Discrimination between ABO blood groups {#Sec9}
---------------------------------------

To define how various assays distinguish between blood groups, we performed non-parametric tests for all three data sets. All glycan-based immunoassays were able to distinguish between blood groups (Fig. [2](#Fig2){ref-type="fig"}). As expected, highly significant differences (*p* \< 0.01) between the known blood group antigens A and B were found in each applied method (SA, ELISA and PGA). Strong discrimination of antibody levels for A~tri~ was observed in all three methods with the highest detected by suspension array (SA, *p* \< 0.0001; PGA, *p* = 0.0004; ELISA, *p* = 0.0004). Less significant discrimination in all three assays were found for B~tri~ (SA, *p* = 0.0058; PGA, *p* = 0.006, ELISA *p* = 0.013). Distribution of anti-A/B antibodies using a pool of immunoglobulin subtypes (IgG, IgA, and IgM) were concordant with classical haemagglutination data \[[@CR35]\]. The accuracy of all applied assays to discriminate between expected anti-glycan antibody levels was evaluated by ROC curves. Based on A~tri~ as a binary classifier, data from blood groups with low anti-A antibody levels (BG A and AB) were combined, as were the data from BG with higher anti-A antibody levels (BG B and O). In contrast, data from blood groups B and AB *versus* blood groups A and O were combined for comparison, based on B~tri~ as the binary classifier. Sensitivity, specificity and Area Under the Curve (AUC) were calculated for each assay as a measure for discriminatory power. Hereby, SA revealed the best discrimination between low and high anti-A antibody levels with excellent selectiveness (sensitivity 93.3%, specificity 93.7%, AUC 0.96; Fig. [2c](#Fig2){ref-type="fig"}). An equal sensitivity, specificity and AUC of 0.95 was achieved for ELISA; PGA revealed a comparably lower sensitivity (86.7%), specificity (87.5%) and AUC (0.93). Interestingly, the overall pattern changed in anti-B antibody levels, and sensitivity, specificity and AUC values decreased for all three methods (PGA, AUC 0.85; SA, AUC 0.87; ELISA, AUC 0.78, respectively) (Fig. [2d](#Fig2){ref-type="fig"}).Fig. 2Binding of plasma anti-A/B antibodies to A~tri~ and B~tri~. Boxplots generated for SA (suspension array), PGA (printed glycan array) and ELISA, demonstrate the distribution of anti-glycan antibodies to glycans A~tri~ (**a**) and B~tri~ (**b**). Blood groups are shown on the x-axis, standardized signals for each method are on the y-axis. Kruskal-Wallis *p*-values indicate the equality of population medians among blood groups. ROC curves for blood groups A and AB (low anti-A antibody levels) *versus* B and O (high anti-A antibody levels) were determined by SA, PGA and ELISA (**c**). Data from blood group B and AB *versus* blood group A and O were combined respectively (**d**)

Expression of ovarian cancer biomarker P~1~ trisaccharide {#Sec10}
---------------------------------------------------------

Based on the findings that anti-A and anti-B antibody profiles represent an assay independent pattern we further investigated one potential ovarian cancer biomarker, which was previously identified by us using PGA in a discovery approach; antigen P~1~ (*Galα1-4Galβ1-4GlcNAcβ*) \[[@CR11]\]. In order to approach this question with appropriate comparative numbers, we increased the cohort of 31 patients where blood groups were known to a cohort of 48 samples, including 23 undifferentiated serous cancer patients of ovarian, tubal and peritoneal origin, totaling to 24 benign and 24 cancer cases (Table [1](#Tab1){ref-type="table"}). Glycan-based assays were plotted against each other and their relationship determined by linear regression analysis. In comparison to the ABO assays, anti-P~1~ correlations across the three assays appeared to be much weaker. The comparison between PGA and SA showed the highest correlation (*r*~ccc~ = 0.55 for the entire cohort, 0.58 for benign and 0.43 for malignant samples, Fig. [3](#Fig3){ref-type="fig"}). The discrimination between control and cancer patients showed the same trend in both SA and PGA with lower anti-P~1~ antibody levels in the cancer cohort (*p* = 0.03 and *p* = 0.004, respectively, Fig. [3](#Fig3){ref-type="fig"}). No improvement in discrimination could be achieved in the comparisons of PGA or SA with ELISA assay (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Anti-P~1~ antibody levels in suspension array and printed glycan array. Boxplots demonstrate the distribution of anti-glycan antibodies directed to P~1~ in benign control (*n* = 24; BD) and cancer plasma samples (*n* = 24; CA) for suspension and printed glycan arrays as well as ELISA

Discussion {#Sec11}
==========

In the current study, which is in continuity of two previous publications of ours using both a newly described PGA and SA \[[@CR11], [@CR21]\], we investigated the efficacy and selectivity of three custom-developed immunoassays to profile anti-glycan antibodies in individual human plasma samples. All three methods adequately reflected the known serological isohaemagglutinin distribution within ABO blood groups, with the best being SA and PGA. The correlation between all three assays was more distinctive for the detection of anti A-antibodies than for anti-B antibodies. Our results indicate that anti-A/B blood group antibodies positively correlated with each other and that all glycan immunoassays could detect these with statistical significance. They demonstrated method-independent tendencies due to their high affinity, which reflects their strong biological importance even in a small patient cohort \[[@CR26]\].

In contrast, anti-P~1~ correlations across the three assays were considerably less pronounced although it was primarily detected by PGA with the highest discriminative power in a discovery approach in non-mucinous ovarian cancers. Nevertheless, with equal control to cancer patient numbers we did improve the correlation of this cancer-specific marker for the comparison of PGA and SA.

The discrepancy between PGA and the other two glycan immunoassays could reflect differences in the assay design, like glycan display, density and surface presentation, as well as the various assay conditions such as temperature, serum dilution, static/dynamic characteristics, and antigen/antibody ratio (Table [2](#Tab2){ref-type="table"}). The most dramatic difference between all three assays appears to be the antibody/antigen ratio. There is an excess of antibodies over antigen in PGA only, whereas in ELISA and SA the ratio of antigen/antibody is opposite (Table [2](#Tab2){ref-type="table"}). As a result, in these two assays all antibodies of a particular specificity are allowed to bind to their glycan ligands on the array. Thus, ELISA and SA are more susceptible to promiscuous binding than PGA, where a competition between antibodies takes place. Additional factors, which play a role in the different binding patterns of the three methods include: 1) temperature; 2) polyethylene glycol (PEG) linking of glycans (in PGA) reducing nonspecific binding similarly to a "stealth" effect in PEGylated liposomes \[[@CR36]\]; 3) flow conditions of SA; 4) random mutual orientation of glycans in a polymeric display (SA and ELISA) in contrast to more restricted orientation of glycans in a PGA monolayer (Table [2](#Tab2){ref-type="table"}). This could indicate that PGA has advantages compared to the other two glycan immunoassays; certainly it demonstrates that each method strongly depends on the task it is used for, taking into account the advantages as well as limitations. SA and PGA both require a lower amount of glycans (at least three orders of magnitude) and SA needs even lower quantities of glycan-binding proteins. Whilst SA and ELISA have a broader flexibility and allow assay reconfigurations, PGA is exceptionally convenient for screening large numbers of yet biologically unknown glycans besides demonstrating low background and a wide dynamic range. Whilst PGA is ideal for a discovery approach, suspension array, which is based on glycosylated fluorescent beads \[[@CR21]\] seems ideal for the diagnostic analysis of human plasma antibodies in a clinical setting. In biomarker discovery studies the use of only one assay with appropriate sensitivity, specificity and reproducibility might be sufficient if validation is performed in a second independent patient cohort. In contrast, crucial conclusions based on data from one assay might not be sufficient in the case of basic research, as each glycan could be showing physiologically important patterns only in one of the other assays. As each method allows a different view into the investigation and specificity of glycan binding patterns \[[@CR6], [@CR37]\] or motif-based analysis of specific glycan-binding proteins \[[@CR38]\], the cumulative method approach seems more preferable. Whilst in datasets obtained with a discovery PGA approach, ELISA and SA assays might be suggested as validation methods, they should be considered as highly controversial and not concordant due to essential differences in assaying conditions.Table 2Comparative conditions of anti-glycan immunoassays\*According to experiments on glycan affinity isolation the range of highest rank human antibodies lies in 1--10 microgram per mL interval (*P. Obukhova et al., Glycoconj J, submitted*)\*\*Calculated for 0.1 mL well in ELISA, 1 mL working volume of sample applied onto microchip, and 50 μl of sample for SA\*\*\*\[[@CR39]\]

This work was supported by Oncosuisse (02115-08-2007 to V.H.S.); Swiss National Foundation (320000-12543 to V.H.S.; PBZHP3-133289 to F.J.); European Science Foundation (V.H.S.); Cancer Institute NSW (09/CRF/2-02 to V.H.S.); Mary Elizabeth Courier Research Scholarship, RANZCOG (to V.H.S.); William Maxwell Trust (to V.H.S.); Cellexicon, Inc. La Jolla, CA, USA (to M.E.H.); National Cancer Institute, USA, grant 1U01CA128526 (to M.E.H); RAS Presidium Program 'Molecular and Cell Biology' (to N.V.B.) and State grant \#2011-1.2-512-013-008 (to N.V.B.).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Nicolai V. Bovin and Viola Heinzelmann-Schwarz contributed equally.
